Pharma DECODED
Previous edition: 12 Apr 2024
Share article
Get the full version straight to your inbox.
Exclusive access to our best-in-class data & intelligence
Subscribe now
Vertex joins pharma immunotherapy deal uptick with $4.9bn Alpine purchase
Alpine’s lead asset, povetacicept, is slated to enter Phase III trials in the second half of this year.
Vertex Pharmaceuticals has agreed to acquire biotech Alpine Immune Sciences for $4.9bn, joining the growing number of pharma spending big on immunotherapy-focused companies.
The gene therapy developer will pay $65 for each Vertex shares, around a 67% premium on the US biotech’s stock’s close on 9 April. Rumours of takeover interest surfaced on 10 April via Bloomberg, with the two companies publicly announcing the board-approved acquisition agreement via a press release the same day.
Alpine’s lead asset is povetacicept, a dual agonist of two cytokines – namely B cell activating factor and a proliferation-inducing ligand. The two proteins, called BAFF and APRIL, play a key role in the development of autoimmune diseases.
The biotech is developing the drug, also dubbed ALPN-303, in renal indications and autoimmune cytopenias. Emerging with high promise is the drug’s efficacy in treating immunoglobulin A nephropathy (IgAN), an autoimmune kidney disease.
Vertex’s CEO Reshma Kewalramani says povetacicept is a "potential best-in-class treatment for IgAN."
He added: "We also look forward to fully exploring povetacicept’s potential as a ‘pipeline-in-a-product' and adding Alpine’s protein engineering and immunotherapy capabilities to Vertex’s toolbox."
Alpine states that preclinical studies have shown that its dual agonist approach has demonstrated higher binding affinity and greater potency than single inhibitors of BAFF and APRIL.
Also announced on the same day as the acquisition was data from Alpine’s Phase I/II RUBY-3 trial (NCT05732402) investigating povetacicept in IgAN. After receiving the drug subcutaneously every four weeks at 80mg, patients had a 64.1% reduction from baseline in urine protein to creatinine ratio, indicating an improvement in proteinuria. Proteinuria is usually an indicator of kidney damage.
Alpine said it has had a successful end-of-Phase II meeting with the US Food and Drug Administration (FDA), opening up the development avenue to a Phase III trial, slated to start in the second half of 2024.
Calliditas Therapeutics’ Tarpeyo (budesonide) is currently the only FDA-approved therapy for IgAN, receiving regulatory approval in December 2023. Tarpeyo is indicated for reducing kidney function loss in IgAN patients at risk of disease progression.
Also ramping up development activities in kidney disease is Novartis, which acquired assets – including Fabhalta (iptacopan) from Chinook Therapeutics in a $3.2bn deal in August 2023. Fabhalta hit its interim endpoint in a Phase III trial last October, with Novartis seeking accelerated approval this year.
Vertex’s acquisition adds to a bustling immunotherapy deal landscape in the pharma industry, with AbbVie, Sanofi and Bristol Myers Squibb also completing billion-dollar deals in the space recently.
Latest news
FDA approves AstraZeneca's FASENRA for asthma in children
The expanded approval of FASENRA for use in younger patients comes after the regulator initially approved the therapy in 2017.
Fujifilm invests $1.2bn ramping up North Carolina facility
The Fujifilm site expansion is set to add 680 jobs to the site and expand Fujifilm’s contract research business and production capacity across North America.
UK's NICE recommends AbbVie's Aquipta to treat migraines
The oral drug, which gained UK approval in September 2023, is used for the prevention of both chronic and episodic migraines.
Rallybio and J&J collaborate to tackle maternal-foetal blood disorder
The collaboration pact will see Rallybio gaining a $6.6m equity investment from J&J to further a natural history study of FNAIT.
Lipocine hopes obesity drug could boost muscle mass in combo with GLP1-RAs
CEO of Lipocine, Dr Mahesh Patel said the company will be meeting with the FDA to discuss future plans for the candidate.
OSE wins French govt grant for Phase III trial for cancer vaccine
The $9m French funding is for the registration Phase III trial for OSE’s Tedopi as a second-line treatment for non-small cell lung cancer (NSCLC).
FDA approves trial of system to measure baby's oxygen during labour
The clinical trial of the Lumerah system is set to begin in April 2024 in Norfolk, Virginia, under FDA IDE.
In our previous edition
Pharma Decoded
Novartis plans to axe 680 employees
11 Apr 2024
Pharma Decoded
Oryzon wins FDA approval to begin SCLC treatment trial
10 Apr 2024
Pharma Decoded
J&J and Legend's Carvykti scores early line approval for MM by FDA
09 Apr 2024
Newsletters in other sectors
Aerospace, Defence & Security
Banking & Payments
Travel and Tourism
Search companies, themes, reports, as well as actionable data & insights spanning 22 global industries
Access more premium companies when you subscribe to Explorer